View our injection videoSomatuline® Depot (lanreotide) Injection is injected in an easy, two-step injection process. Learn more about how easy it is to inject Somatuline Depot.
While your healthcare professional may adjust your dosage periodically, treating a condition like acromegaly is something you may continue for the rest of your life.
The good news is that, with medication and surgery or radiation, acromegaly can be controlled long-term. Also with treatment, people with acromegaly may live longer than those who go untreated.
Like all other medications, Somatuline® Depot (lanreotide) Injection can cause side effects. Learn about possible side effects of Somatuline Depot.
If you take Somatuline® Depot (lanreotide) Injection for acromegaly, you are not alone. Learn about resources available to you.
Learn about insurance coverage, pharmacies that carry Somatuline® Depot (lanreotide) Injection, and the Reimbursement Hotline.
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline® Depot (lanreotide) Injection 60mg.
There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline® Depot (lanreotide) Injection may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.
Please see Full Prescribing
Information for additional important information.
Home |
Full Prescribing Information |
Privacy Policy |
Site User Guide |
Sitemap |
Legal Notices |
Privacy StatementSOMATULINE® DEPOT (LANREOTIDE) INJECTION IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).
THIS WEB SITE IS INTENDED FOR US RESIDENTS ONLY. TERCICA, INC. ALL RIGHTS RESERVED.
© 2008 Tercica Legal Notices | Privacy Statement